 |
|
Guest Authorship and Ghostwriting in Publications Related to RofecoxibA Case Study of Industry Documents From Rofecoxib Litigation
Joseph S. Ross, MD, MHS;
Kevin P. Hill, MD, MHS;
David S. Egilman, MD, MPH;
Harlan M. Krumholz, MD, SM
JAMA. 2008;299(15):1800-1812.
Context Authorship in biomedical publication provides recognition and establishes accountability and responsibility. Recent litigation related to rofecoxib provided a unique opportunity to examine guest authorship and ghostwriting, practices that have been suspected in biomedical publication but for which there is little documentation.
Objective To characterize different types and the extent of guest authorship and ghostwriting in 1 case study.
Data Sources Court documents originally obtained during litigation related to rofecoxib against Merck & Co Inc. Documents were created predominantly between 1996 and 2004. In addition, publicly available articles related to rofecoxib identified via MEDLINE.
Data Extraction All documents were reviewed by one author, with selected review by coauthors, using an iterative process of review, discussion, and rereview of documents to identify information related to guest authorship or ghostwriting.
Data Synthesis Approximately 250 documents were relevant to our review. For the publication of clinical trials, documents were found describing Merck employees working either independently or in collaboration with medical publishing companies to prepare manuscripts and subsequently recruiting external, academically affiliated investigators to be authors. Recruited authors were frequently placed in the first and second positions of the authorship list. For the publication of scientific review papers, documents were found describing Merck marketing employees developing plans for manuscripts, contracting with medical publishing companies to ghostwrite manuscripts, and recruiting external, academically affiliated investigators to be authors. Recruited authors were commonly the sole author on the manuscript and offered honoraria for their participation. Among 96 relevant published articles, we found that 92% (22 of 24) of clinical trial articles published a disclosure of Merck's financial support, but only 50% (36 of 72) of review articles published either a disclosure of Merck sponsorship or a disclosure of whether the author had received any financial compensation from the company.
Conclusions This case-study review of industry documents demonstrates that clinical trial manuscripts related to rofecoxib were authored by sponsor employees but often attributed first authorship to academically affiliated investigators who did not always disclose industry financial support. Review manuscripts were often prepared by unacknowledged authors and subsequently attributed authorship to academically affiliated investigators who often did not disclose industry financial support.
Author Affiliations: Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, New York (Dr Ross); Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, and McLean Hospital, Belmont, Massachusetts (Dr Hill); Department of Community Health, Brown University School of Medicine, Providence, Rhode Island (Dr Egilman); and Robert Wood Johnson Clinical Scholars Program and Section of Cardiovascular Medicine, Department of Medicine, Section of Health Policy and Administration, School of Public Health, Yale University School of Medicine, and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut (Dr Krumholz).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Garret A. FitzGerald
JAMA. 2008;300(8):900-901.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Carlo Patrono
JAMA. 2008;300(8):901.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Christopher J. Hawkey
JAMA. 2008;300(8):901.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Steven Ferris, Douglas Galasko, and Louis Kirby
JAMA. 2008;300(8):901-902.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Richard Balon
JAMA. 2008;300(8):902.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Serban-Dan Costa
JAMA. 2008;300(8):902-903.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
Catherine D. DeAngelis and Phil B. Fontanarosa
JAMA. 2008;300(8):905-906.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
Bruce M. Psaty and Richard A. Kronmal
JAMA. 2008;299(15):1813-1817.
ABSTRACT
| FULL TEXT
Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence
Catherine D. DeAngelis and Phil B. Fontanarosa
JAMA. 2008;299(15):1833-1835.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Ghosts in the Machine: Comment on Sismondo
McHenry
Social Studies of Science 2009;39:943-947.
Ghosts in the Machine: Reply to McHenry (2009)
Sismondo
Social Studies of Science 2009;39:949-952.
Requirements and Definitions in Conflict of Interest Policies of Medical Journals
Blum et al.
JAMA 2009;302:2230-2234.
ABSTRACT
| FULL TEXT
Ethical Issues in Cardiovascular Research Involving Humans
Frye et al.
Circulation 2009;120:2113-2121.
FULL TEXT
Better regulation of industry-sponsored clinical trials is long overdue.
Wynia and Boren
J Law Med Ethics 2009;37:410-419.
Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals
Hirsch
Mayo Clin Proc. 2009;84:811-821.
FULL TEXT
How do potential conflicts of interest confuse medicine and public health?: How could disclosure of interests work better in medicine, epidemiology and public health?
Marcovitch
J. Epidemiol. Community Health 2009;63:608-609.
FULL TEXT
Science journal editors' views on publication ethics: results of an international survey
Wager et al.
J. Med. Ethics 2009;35:348-353.
ABSTRACT
| FULL TEXT
Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals
Mello et al.
NEJM 2009;360:1557-1566.
FULL TEXT
Ghosts in the machine: publication planning in the medical sciences.
Sismondo
Social Studies of Science 2009;39:171-198.
ABSTRACT
Professional Medical Associations and Their Relationships With Industry: A Proposal for Controlling Conflict of Interest
Rothman et al.
JAMA 2009;301:1367-1372.
ABSTRACT
| FULL TEXT
Vulnerability in clinical research with patients in pain: a risk analysis.
Tait
J Law Med Ethics 2009;37:59-72.
'Ghostbusting' at Blood
Dunbar and Tallman
Blood 2009;113:502-503.
FULL TEXT
Changing of the Guard: New Editor for Archives of Internal Medicine
Greenland
Arch Intern Med 2008;168:2401-2401.
FULL TEXT
Prescription Drugs, Products Liability, and Preemption of Tort Litigation
DeAngelis and Fontanarosa
JAMA 2008;300:1939-1941.
FULL TEXT
The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration
Ogrinc et al.
Qual Saf Health Care 2008;17:i13-i32.
ABSTRACT
| FULL TEXT
Industry-Sponsored Negative Trials and the Potential Pitfalls of Post Hoc Analysis
Tribble
Arch Surg 2008;143:933-934.
FULL TEXT
Differential Citation Rates of Major Cardiovascular Clinical Trials According to Source of Funding: A Survey From 2000 to 2005
Conen et al.
Circulation 2008;118:1321-1327.
ABSTRACT
| FULL TEXT
Industry-Sponsored Clinical Research: A Broken System
Angell
JAMA 2008;300:1069-1071.
FULL TEXT
Authorship: why not just toss a coin?
Strange
Am. J. Physiol. Cell Physiol. 2008;295:C567-C575.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Patrono
JAMA 2008;300:901-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Balon
JAMA 2008;300:902-902.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
DeAngelis and Fontanarosa
JAMA 2008;300:905-906.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
FitzGerald
JAMA 2008;300:900-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hawkey
JAMA 2008;300:901-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Ferris et al.
JAMA 2008;300:901-902.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Costa
JAMA 2008;300:902-903.
FULL TEXT
The ADVANTAGE Seeding Trial: A Review of Internal Documents
Hill et al.
ANN INTERN MED 2008;149:251-258.
ABSTRACT
| FULL TEXT
Pharmaceutical Promotion and First Amendment Rights
Troy et al.
NEJM 2008;359:536-537.
FULL TEXT
Who is an author?
Swedberg
Eur J Heart Fail 2008;10:523-524.
FULL TEXT
Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence
DeAngelis and Fontanarosa
JAMA 2008;299:1833-1835.
FULL TEXT
|
